<table>
<thead>
<tr>
<th>Poster Program</th>
</tr>
</thead>
</table>
| **[P1.001]** Proposing a new conceptual syndemic framework for COVID-19 vaccine hesitancy: a narrative review  
Bara' AlShurman*, Zahid Butt, University of Waterloo, Canada |
| **[P1.002]** Application of electron beam technology to develop vaccines to control foodborne pathogens in broiler chickens  
Ruvindu Perera¹, Anna Assumpcao¹, Komala Arsi², Annie Donoghue³, Suresh Pillai⁴, Palmy Jesudhasan*³, ¹University of Arkansas, USA,²United States Department of Agriculture, USA,³United States Department of Agriculture, USA,⁴Texas A&M University System, USA |
| **[P1.003]** A systematic review of interventions to improve vaccination uptake among adults  
Anelisa Jaca*¹, Lindi Mathebula¹, Julie Jacobson Vann², Masibulele Sishuba³, Thobile Malinga¹, Charles Wiysonge¹, Duduzile Ndwandwe¹, ¹South African Medical Research Council, South Africa,²University of Carolina, USA,³South African Medical Research Council, South Africa |
| **[P1.004]** A qualitative study exploring motivators and barriers to COVID-19 vaccine uptake among adults in South Africa and Zimbabwe  
Nellie Myburgh¹, Mamakiri Mulaudzi¹, Gugulethu Tshabalala¹, Norest Beta², Kimberley Gutu¹, Stefanie Vermaak¹, Charles Lau³, Lawrence Stanberry*⁴, Catherine Hill¹, James Wilmot⁴, Shabir Madhi¹, Tariro Makadzange², Janan Dietrich⁵,¹ University of the Witwatersrand, South Africa,²Charles River Medical Group, Harare, Zimbabwe,³Research Triangle International (RTI), USA,⁴Columbia University, USA,⁵Health Systems Research Unit, South African Medical Research Council, Bellville, South Africa |
[P1.005] A community-based volunteer service to reduce inequity in COVID-19 vaccine distribution in New York City
Stasha O’Callaghan*1, Madalyn Fernbach2, Haidee Chen3, Jade Tapia4, Charis Ng5, Ee Tay6,4, 1New York City Health and Hospitals Corporation, USA, 2Penn State School of Medicine, USA, 3Columbia University, USA, 4NYU Langone Health, USA, 5SUNY Downstate Health Sciences University, USA, 6Bellevue Hospital Center, USA

[P1.007] Promising practices for engaging local faith actors to promote uptake of COVID-19 vaccination: Lessons learned from Ghana, Indonesia, Sierra Leone, and Uganda
Mona Bormet*1, Carolyn O'Brien2, Sara Melillo3, 1Christian Connections for International Health (CCIH), Kenya, 2Christian Connections for International Health, USA, 3Independent Global Health Consultant, Uganda

[P1.008] Culturally tailored COVID-19 vaccine clinics: a Community Oriented Primary Care (COPC) approach to increase vaccination rates among Latinos in the United States
Armando De Alba*1, Reyna L. Reyes-Nunez2, 1University of Nebraska Medical Center, USA, 2University of Nebraska Omaha, USA

[P1.009] Vaccine development at the biomedical advanced research and development authority (BARDA)
Rushyannah Killens-Cade*, Adam Clark, Daniel Wolfe, Biomedical Advanced Research and Development Authority, USA

[P1.010] Factors associated with primary and follow-up booster COVID-19 vaccination in a community sample of African American men and women in the United States midwest
Jeffrey Kelly*, Jennifer Walsh, Katherine Quinn, Yuri Amirkhanian, Monique Plears, Kevin Brown, Medical College of Wisconsin, USA
[P1.011] Interaction and antiviral treatment of coinfection between SARS-CoV-2 and influenza in vitro
Danlei Liu*, Ka Yi Leung, Hoi Yan Lam, Ruiqi Zhang, Yujing Fan, Xiaochun Xie, Kwok Hung Chan, Ivan Hung, The University of Hong Kong, Hong Kong

[P1.012] The role of immunization information systems in improving equitable vaccine uptake, and the evidence-based policy and technical attributes that enable them to do so
Alexandra Bhatti¹,², Amanda L. Eiden¹*, Luke Cunniff¹, Merck & Co Inc, USA, Arizona State University, USA

[P1.013] To assess common side effects of -19 vaccine experienced by people in Dedza in Malawi
Robert Msokwa*, Mzuzu University, Malawi, University of Malawi, Malawi

[P1.014] Epitope-enrichment plus a proper adjuvant-regimen induced potent antigen-specific memory responses in mice
Hong Ling¹*, Yan Li¹, Fu-Ning Liu¹, Xin-Yue Zhao¹, Yong Zhang², Jia-Ye Wang¹, Min Zhuang¹, Harbin Medical University, China, Jilin University, China

[P1.015] The inclusion of pregnant women in vaccine clinical trials: a 5-year overview of late-stage clinical trials’ records
Maha Salloum¹*, Antea Paviotti¹, Hilde Bastiaens², Jean-Pierre Van Geertruyden¹, University of Antwerp, Belgium, University of Antwerp, Belgium

[P1.016] COVID-19 vaccine intentions among Métis parents of children under 11 years old in Ontario, Canada
Noel Tsui¹,², Abigail Simms¹,², Sarah Edwards¹,², Shelley Cripps¹, Métis Nation of Ontario, Canada, Institute for Clinical Evaluative Sciences, Canada
[P1.017] Ethnic disparities in COVID-19 vaccine mistrust and receipt in British Columbia, Canada
Bushra Mahmood*1, Prince Adu2, Geoffrey McKee2, Aamir Bharmal2,1, James Wilton2, Naveed Janjua2,1,3, 1The University of British Columbia, Canada, 2BC Centre for Disease Control, Canada, 3Centre for Health Evaluation and Outcome Sciences, St. Paul's Hospital, Canada

Abigail Simms*1,2, Keith King3, Noel Tsui1,2, Sarah Edwards1,2, Graham Mecredy1, 1Institute for Clinical Evaluative Sciences, Canada, 2Métis Nation of Ontario, Canada, 3University of Alberta, Canada

[P1.019] Effect of revision of the recommended vaccination schedule for preventing vertical transmission of hepatitis B virus on vaccination and infection status of infants in Japan
Hayato Yamana*1, Sachiko Ono2, Nobuaki Michihata3, Kohei Uemura2, Hideo Yasunaga2, 1Jichi Medical University, Japan, 2The University of Tokyo, Japan, 3Chiba Cancer Center Research Institute, Japan

[P1.020] Understanding and explaining the link between anthroposophy and vaccine hesitancy: A systematic review
Sibylle Herzig van Wees*1, Khadija Abunnaja1, Sandra Mounier-Jack2, 1Karolinska Institute, Sweden, 2London School of Hygiene & Tropical Medicine, UK

[P1.021] A rapid risk-benefit assessment system for large-scale vaccine implementation in response to pandemics
Keun-Young Yoo*1,2, Sun Bean Kim3, Jaehun Jung4, 1Veterans Health Service Medical Center, Republic of Korea, 2Seoul National University College of Medicine, Republic of Korea, 3Korea University College of Medicine, Republic of Korea, 4Department of Preventive Medicine, Gachon University, Republic of Korea
[P1.022] Development of a cross-clade pan-sarbecovirus booster vaccine
Feng Zhu*, Chee Wah Tan†, Wan Ni Chia†, Lin-Fa Wang†,‡
†Duke-NUS Medical School Program in Emerging Infectious Diseases, Singapore, ‡Singhealth Duke-NUS Global Health Institute, Singapore

[P1.023] Implementation of an EPI/PEI synergy model for improving immunization in the peri-urban areas of Karachi: A case study
Rakhshanda Ishaque*, Vital Pakistan Trust, Pakistan

[P1.024] COVID-19 vaccine hesitancy among unvaccinated or partially vaccinated adults in Ethiopia
Aderaw Anteneh*, Anteneh Getachew†, Amel Hashim†, Misael Kenera†, Erica Felker-Kantor‡, †Population Services International, Ethiopia, ‡Population Services International, USA

[P1.025] A shot in the arm, not a shot in the dark! A systems perspective of an apex Indian medical institution's COVID-19 vaccination programme
Parmeshwar Kumar*, Vikas Hanumanthappa†, Naveen Gowda‡, Rudresh Suddekenthe³, Pallavi Chamoli†, Varsha Kashyap†, Kamal Gulati†, Anju Jain†, Sunita Dua†, Nirupam Madaan†, Karan Madan†, Aarti Vij‡, Rakesh Kumar†, Randeep Guleria⁴, †All India Institute of Medical Sciences, India, ‡Apollo Specialty Hospitals Pvt Ltd, India, ³SDM College of Medical Sciences, India, ⁴Medanta The Medicity, India

[P1.026] Juxtaposing Pareto’s principle over SWOT analysis to determine factors to improve COVID-19 vaccination uptake: A 4C model of vaccine hesitancy
Parmeshwar Kumar*, Pallavi Chamoli†, Varsha Kashyap†, Ayesha Choudhary², Randeep Guleria³, †All India Institute of Medical Sciences, India, ‡Stanford University, USA, ³Medanta The Medicity, India
[P1.027] COVID-19 vaccine confidence and associated factors among adults with hypertension or Diabetes Mellitus in Kilimanjaro region, Tanzania
Monica Mtei*, Daimon Mwasamila, Caroline Amour, Julieth Bilakwate, Laura Shirima, Amina Farah, Innocent Mboya, Fabio Candotti, Johnston George, Sia Msuya, Kilimanjaro Christian Medical University College, Tanzania, United Republic of, London School of Hygiene and Tropical Medicine, UK, Kilimanjaro Christian Medical University College, UK, University of Lausanne, Switzerland, Kilimanjaro Christian Medical Centre, Tanzania, United Republic of, Lund University, Sweden, University of Lausanne, Basel, Switzerland, Institute of Public Health, Department of Epidemiology and Biostatistics, Kilimanjaro Christian Medical University College, Moshi, Tanzania, United Republic of

[P1.028] Using volunteers to combat vaccine hesitancy online: evaluation of a randomized intervention
Hinna Hasan, Kirsten Cornelson, Janette Wong, Madison Fullerton, Theresa Tang, Chelsea D'Silva, Jia Hu, 19 to Zero, Canada, Western University Ivey Business School, Canada, University of Calgary, Canada

[P1.029] Evaluation of animal-origin free peptones to enhance viral vector vaccine production
Syed Khalil*, Wen-Yang Tsai, Ashwin Gurunathan, Matt Rosecrans, Aaron Robinson, Anna-Barbara Hachmann, Stacy Holdread, James Brooks, Thermo Fisher Scientific, Hunt Valley, Maryland, USA

[P1.030] Analysing vaccine rumours: the r/osi framework
Sibylle Herzig van Wees*, Karolinska Institute, Sweden

[P1.031] A systematic review of factors that influence parents' views and practices around routine childhood vaccination in Africa: a qualitative evidence synthesis
Edison Mavundza*, Sara Cooper, Charles Wiysonge, South African Medical Research Council, South Africa
Dual decision-making routes for COVID-19 and influenza vaccines uptake in parents
Jiehu Yuan*, Meihong Dong, Dennis Kai Ming Ip, Hau Chi So, Benjamin John Cowling, Wendy Wing Tak Lam, Qiuyan Liao, 1University of Hong Kong, Hong Kong, 2Laboratory of Data Discovery for Health, Hong Kong Science and Technology Park, Hong Kong

Development of a filamentous bacteriophage-based vaccine displaying the MAGE-A1 tumour peptide for the treatment of malignant melanoma cancer
Nuša Brišar*, Katja Šuster, Simona Kranjc Brezar, Andrej Cör, 1University of Primorska, Slovenia, 2University of Ljubljana, Slovenia, 3Valdoltra Orthopaedic Hospital, Slovenia, 4Institute of Oncology Ljubljana, Slovenia

Recombinant group a carbohydrate backbone embedded into outer membrane vesicles is a potent vaccine candidate targeting group a streptococcus from streptococcus pyogenes and streptococcus dysgalactiae subsp. equisimilis
Sowmya Ajay Castro*, Sarah Thomson, Alexandra H Shaw, Azul Zorzoli, Benjamin H Meyer, Mark Reglinski, Helge C Dorfmueller, 1University of Dundee, UK, 2The National Institute of Biological Standards and Control, UK, 3Royal Infirmary of Edinburgh, UK

Vaccine hesitancy in adults in the United States: a quantitative survey study
Anthony DiFranzo, deMauri S. Mackie, Alexandra Bhatti, Kushal Modi, Amanda L. Eiden*, 1Merck & Co., Inc., Rahway, NJ, USA, 2Cerner Enviza, an Oracle Company, Malvern, PA, USA

Significance of collaborative efforts between NGOs/CSOs and Government in maximizing reach for vaccination of ‘Zero-dose ‘children: Lessons of CORE Group Partners Project, India
Jitendra Awale*, Dr Roma Solomon, Manojkumar Choudhary, Rina Dey, CORE Group Partners Project, India
Reactogenicity of third and fourth booster doses of HIPRA PHH-1V, an adjuvanded bivalent recombinant protein vaccine against SARS-CoV-2
Salomé de Cambra*, Júlia Corominas, Maria Teresa Prat, Irina Güell, Laura Ferrer, HIPRA HUMAN HEALTH, Spain, HIPRA HUMAN HEALTH, Spain

Building vaccine confidence among government frontline workers (Accredited Social Health Activists - ASHAs) to address vaccine hesitancy and accelerate the uptake of childhood immunization: Experience of CORE Group Partners Project Project, India
Manojkumar Choudhary*, Roma Solomon, Jitendra Awale, Rina Dey, CORE Group Partners Project, India

Recovery of childhood immunization disrupted by COVID-19 pandemic - core group partners project’s learnings from four districts of Uttar Pradesh, India
Parul Ratna*, Deepti Pant, CORE Group Partners Project’s, India, Catholic Relief Services, India

Influx of zero-dose children during and post COVID-19 pandemic: How CORE Group Partners Project supported the government mission to overcome the challenge in high priority sub-centers in Uttar Pradesh, India
Yatender Singh*, Roma Solomon, Praveen Kaushik, Mohd Javed, Project Concern International/PCI, India, CORE Group Partners Project (CGPP), India, CORE Group Partners Project, India, Society For All round Development, India, Jan Kalyan Samiti, India

Modelling the potential health impact of prospective Strep A vaccines
Fiona Giannini, Jeffrey Cannon, Daniel Cadarette, David Bloom, Hannah Moore, Jonathan Carapetis, Kaja Abbas*, University of Western Australia, Australia, Harvard University, USA, Curtin University, Australia, Perth Children's Hospital, Australia, London School of Hygiene & Tropical Medicine, UK
[P1.042] Adult respiratory illness attendances to emergency departments: The pinnacle of winter pressures
Hannah Wright*1, Hamish Graham1, James Campling2, Elizabeth Begier3, Andrew Vyse4, Charlie Reynard5, Mary Slack6,7, Alethea De Melo8, Gillian Ellsbury8, 1Vaccines Medical Affairs, Pfizer UK, UK,2Vaccines Medical Affairs, Pfizer UK, UK,3Global Medical and Scientific Affairs, Pfizer Inc, Ireland,4Vaccines Medical Affairs, Pfizer Vaccines, UK,5Vaccines Medical Affairs, Pfizer, UK, UK,6School of Medicine and Dentistry, Griffith University - Gold Coast Campus, Australia,7Global Scientific Affairs, Pfizer Inc, UK,8Vaccines Medical Affairs, Pfizer Vaccines, UK, UK

[P1.043] Evaluation of COVID-19 vaccines and infection in HIV patients
Muhammed Fatih Karasin, Zeynep Bayraktar, Müge Toygar Deniz, Nazlıgül Özgökçē, Mehmet Kağan Özdemir, Sila Aakhan*, Kocaeli University School of Medicine, Turkey

[P1.044] A systematic scoping review to identify criteria to assess a country’s readiness to deploy a new or under utilised vaccine at a national level
Alexandra Bhatti1, Amanda L. Eiden*1, Vaneesha Monk2, Rachel Mitrovich1, Lindsay V. Hermany1, Natasha Hansen1, Mark Connolly3, Samantha Vanderslott2, Luke Baxter2, Aomesh Bhatt2, 1Merck & Co Inc - Rahway, USA,2University of Oxford, UK,3Global Market Access Solutions Sarl, Switzerland

[P1.045] COVID-19 vaccination hesitancy in adults with a history of cancer
Mohamed Elsaid*1, Chloe Hery1, Xiaochen Zhang2, Cecilia DeGraffinreid1, Electra Paskett3,4, 1The Ohio State University, USA,2Fred Hutchinson Cancer Research Center Cancer Prevention Program, Seattle, WA, USA,3Department of Internal Medicine, Division of Cancer Prevention and Control, USA,4Cancer Control Continuum in Ohio and Indiana Consortium, USA
[P1.046] Bacterium-like particles as a promising adjuvant for nasal vaccines targeting intestinal infections
Keita Takahashi*, Haruka Sudo, Ayato Tsujii, Nagisa Tokunoh, Sarana Kawashima, Yuta Hayakawa, Hiroki Fukushima, Naoki Inoue, Tetsuo Koshizuka, Gifu Pharmaceutical University, Japan

Sara Al-Dahir*, Tahseen Hasan, Alaa Khalil, Xavier University of Louisiana, USA, Johns Hopkins University, USA, Iraq Ministry of Health, Iraq, Nunez Community College, USA

[P1.048] The test-negative design case-control study of the effectiveness of BNT162b2 vaccine against symptomatic SARS-CoV-2 infection in children aged 5–11 years in Japan during Omicron variant predominate periods
Megumi Hara*, Yuko Ohta, Naoki Fusazaki, Yoshio Hirota, Saga University, Japan, Ohta Yuko clinic, Japan, Ohta Yuko clinic, Japan, Clinical Epidemiology Research Center, SOUSEIKAI Medical Group, Japan

[P1.049] Increasing understanding of the role of engineering in vaccine development and manufacture. A collaborative project between UCL-Oxford Future Vaccine Manufacturing Research Hub (Vax-Hub) and UK secondary schools
Stephen A Morris*, Ludovica Vaiarelli, Salome De Sa Magalhaes, Martina Micheletti, University College London, UK

[P1.050] Safety of two doses BNT162b2 mRNA vaccine given 21 days apart in children 5 to 11 years old
Chee Fu Yung*, Kai Qian Kam, Seyed Ehsan Saffari, Michelle Ren, Qing Lin Tan, Szu-Tien Thio, Chia Yin Chong, KK Women's and Children's Hospital, Singapore, Duke-NUS Medical School, Singapore, Lee Kong Chian School of Medicine, Singapore, National University of Singapore, Singapore, Duke-NUS Medical School Centre for Quantitative Medicine, Singapore
[P1.051] **(In)congruities in caregivers’ and healthcare providers’ vaccine information approaches: Evidence from a mixed methods study in the Philippines**
Jonas Wachinger*1, Mark Donald C Reñosa2,3, Vivienne Endoma3, Jhoys Landicho-Guevarra3, Maria Paz Demonteverde3, Catherine Silvestre3, Jeniffer Landicho3, Mila F Aligato3, Thea Andrea Bravo3, Jerric Rhazel Guevarra3, Rachel P Chase4, Shannon A McMahon4,5, 1Heidelberg University, Germany, 2Heidelberg Institute of Global Health, Heidelberg University, Germany, 3Research Institute for Tropical Medicine, The Philippines, 4Heidelberg University, Germany, 5Johns Hopkins University, USA

[P1.052] **Humoral immune response against SARS-CoV-2 variants (Omicron BA.1, BA.4/5, Beta and Delta) of PHH-1V booster vaccine in subjects previously vaccinated with a mRNA vaccine. Results of a randomised controlled trial up to 6 months**
Antonio Barreiro*, Antoni Prenafeta, Alexandra Moros, Laia Madrenas, Manuel Cañete, Júlia Corominas, Teresa Prat, Laura Ferrer, HIPRA, Spain

[P1.053] **Humoral immunogenicity of COVID-19 mRNA vaccines: a prospective study focusing on blood selenium and vitamin D levels at baseline**
Goki Yamada*, Akiko Matsumoto2, Takuma Furukawa3,4, Chiharu Iwasaka3,5, Takeshi Sawada3, Mikiko Tokiya2, M.Said Ashenagar3, Mikako Horita3, Tadayuki Tsujita3, Megumi Hara3, 1Kagoshima University, Japan, 2Saga University School of Medicine, Japan, 3Saga University, Japan, 4Saga University Hospital, Japan, 5National Institutes of Biomedical Innovation, Health and Nutrition, Japan

[P1.054] **T cell vaccines against Zika virus**
Branka Grubor-Bauk*, Zelalem Mekonen2, Arthur Yeow2, Wilfred Saron2, Dawn Whelan1, Ryan Santos1, Makutiro Masavuli1, Andreas Suhrbier3, Ashley St John2, Eric Gowans1, David O’Connor4, 1The University of Adelaide, Australia, 2Duke-NUS Medical School, Singapore, 3QIMR Berghofer Medical Research Institute, Australia, 4University of Wisconsin-Madison, USA
[P1.055] Descriptive epidemiology of adverse events following immunization (AEFI) with the Japanese encephalitis vaccination using open data in Japan
Ai Hayashi*1,2, Fuka Kikuchi1,3, Saeko Morino1, Mai Okuyama1, Miho Shibamura1, Sayaka Takanashi1, Satoru Arai1, Hajime Kamiya1, Motoi Suzuki1, National institute of infectious diseases Center for surveillance, immunization, and epidemiologic research, Japan,2Tohoku University, Japan,3Tokyo University of Agriculture and Technology, Japan

Daniela Manno*1, Philip Ayieko1,2, David Ishola1,3, Muhammed O. Afolabi1,3, Frank Baiden1,3, Daniel Tindanbil1,3, Abu Bakarr Kamara4,3, Osman Mohamed Bah4,3, Baimba Rogers4,3, Kwabena Owusu-Kyei1,3, Abdoulie Drammeh1,3, Catriona Patterson1, Kevin Tetteh1, Mattu Tehtor Kroma4,3, Godfrey Tuda Otieno1,3, Bolarinde Joseph Lawal1,3, Auguste Gaddah5, Gibrilla Fadlu Deen Deen4, Babajide Keshinro6, Yusupha Njie1,3, Dickens Kowuro1,3, Brett Lowe1,7, Cynthia Robinson6, Bailah Leigh4, Chris Drakeley1, Brian Greenwood1, Deborah Watson-Jones1,2, London School of Hygiene & Tropical Medicine, UK,2Mwanza Intervention Trials Unit, Tanzania, United Republic of,3EBOVAC Project, Kambia district, Sierra Leone,4University of Sierra Leone, Sierra Leone,5Janssen Research and Development, Beerse, Belgium,6Janssen Vaccines and Prevention BV, The Netherlands,7KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya

[P1.057] Modelling the potential impact of 100 days mission and broader investments on the COVID-19 pandemic
Gregory Barnsley*1,2, Daniela Olivera Mesa2, Damian Walker3,4, Andy Torkelson5, Azra Ghani2, Oliver J Watson2,1, London School of Hygiene and Tropical Medicine Department of Infectious Disease Epidemiology, UK,2Imperial College London, UK,3Management Sciences for Health, USA,4Center for Global Development, USA,5Linksbridge, SPC, USA
[P1.058] Expanding vaccination provider types and administration sites can increase vaccination uptake: A systematic literature review of the evidence outside of the United States
Anna Larson¹, Priya Shanmugam², Rachel Mitrovich¹, Divya Vohra², Aimee Lansdale², Amanda L. Eiden*¹, ¹Merck & Co., Inc., Rahway, NJ, USA, ²Mathematica Inc, USA

[P1.059] Interferon-beta integrated SARS-CoV-2 vaccine prevents co-infection and enhances T-cell immunity in animal model
Wan-Man Wong*¹,², Chun-Kit Yuen¹,², Long-Fung Mak¹,², Kin-Hang Kok¹,², ¹The University of Hong Kong, Hong Kong, ²Centre for Virology, Vaccinology and Therapeutics, Hong Kong Science and Technology Park, Hong Kong

[P1.061] Building confidence in mRNA vaccines through targeted education for employers and vulnerable communities
Chelsea D'Silva¹, Jia Hu*¹, Scott Ratzen², Ajit Johal³, Theresa Tang¹, Hinna Hasan¹, ¹19 to Zero, Canada, ²City University of New York, USA, ³Immunize.io, Canada

[P1.062] Unconjugated peptide vaccine comprising conserved epitopes from both SARS-CoV-2 and influenza virus generates durable and broadly reactive antibodies to multiple coronavirus and influenza virus strains
Nimisha Rikhi*¹, Clara J. Sei¹, Kevin Muema¹, Kellie A. Kroscher¹, Richard F. Schuman², Aba Assiaw-Dufu¹, Gerald W. Fischer¹, ¹Longhorn Vaccines and Diagnostics, LLC, USA, ²Antibody and Immunoassay Consultants, USA

[P1.063] A custom phage immunoprecipitation sequencing library to monitor and observe epitope-level antibody response to SARS-CoV-2 vaccination or infection
Charles Kevin Tiu*¹,², Wanni Chia¹, Feng Zhu¹, Lin-Fa Wang¹,², ¹Duke-NUS Medical School, Singapore, ²Singhealth Duke-NUS Global Health Institute, Singapore
[P1.064] Sociodemographic correlates of vaccination uptake for key vaccine preventable diseases among sexual and gender minorities in living in New Jersey and New York
Kristen Krause*1,2, Anita Karr3, Paul D'Avanzo3, Perry Halkitis1,2, 1Rutgers School of Public Health, USA, 2Rutgers Center for Health, Identity, Behavior and Prevention Studies, USA, 3Columbia University, USA

[P1.065] Assessing concern around MPOX accompanied by acceptability and accessibility of MPOX vaccination among sexual and gender minorities living in New Jersey and New York
Perry Halkitis1,2, Kristen Krause*1,2, 1Rutgers School of Public Health, USA, 2Rutgers Center for Health, Identity, Behavior and Prevention Studies, USA

[P1.066] A rational design of a pneumococcal multi-epitope vaccine: from immunobioinformatics to bench-scale
Vítor Alves*1,2, Enéas Carvalho2, Vinicius Souza2, Jose Patane1, Viviane Gonçalves2, 1University of São Paulo, Brazil, 2Butantan Institute, Brazil

[P1.067] A roundtable discussion on approaches to measuring and improving vaccine confidence globally
Jia Hu*1, Scott Ratzan2, Ajit Johal3, Theresa Tang1, Chelsea D'Silva1, 19 to Zero, Canada, 2City University of New York, USA, 3Immunize.io, Canada

[P1.068] A recombinant, non-replicating oral rotavirus vaccine for the developing world
Esmeralda Cuevas Juarez*, Gilad Doitsh, Emery Dora, Laura Showalter, Ermin Zhao, William Sun, Elena Neuhaus, Molly Braun, Samanta Gutierrez, Sarah Tedjakusuma, Becca Flitter, Sean Tucker, Vaxart Inc, USA
[P1.069] Development of a next generation 31 valent pneumococcal conjugate vaccine (VAX-31) using site-specific carrier protein conjugation
Christopher Behrens*1, Jeff Fairman1, Paresh Agarwal1, Shylaja Arulkumar1, Sandrine Barbanel1, Leslie Bautista1, Aym Berges1, John Burky1, Peter Davey1, Chris Grainger1, Sherry Guo1, Samantha Iki1, Mark Iverson1, Neeraj Kapoor1, Olivier Marcq2, Thi-Sau Migone1, Lucy Pill-Pepe1, Mohammed Sardar1, Paul Sauer1, James Wassil1, 1Vaxcyte Inc., USA, 2Tubulis GmbH, Germany

[P1.070] Immunoglobulin Fc displayed modified Porcine Epidemic Diarhoea Virus (PEDV) enhanced the immune response against PEDV
Kyoung-Ho Lee*1,2, Mai Wada2, Hyun-Jin Shin3, 1Chungnam National University, Republic of Korea, 2CellEnVax, Republic of Korea, 3Chungnam National University, Republic of Korea

[P1.071] An attenuated vaccinia vaccine encoding the SARS-CoV-2 spike protein elicits broad and durable immune responses, and protects cynomolgus macaques and human ACE2 transgenic mice from SARS-CoV-2 and its variants
Fumihiko Yasui*1, Hirohito Ishigaki2, Misako Nakayama2, Naoki Yamamoto1, Kenzaburo Yamaji1, Yusuke Metsumoto1, Cong Nguyen2, Yoshinori Kitagawa2, Takahiro Sanada1, Tomoko Honda1, Tsubasa Munakata1, Yasushi Itoh2, Michinori Kohara1, 1Tokyo Metropolitan Institute of Medical Science, Japan, 2Shiga University of Medical Science, Japan
[P1.072] Defense mechanisms against MERS-CoV infection and immunological memory in mucosal tissues for developing intranasal vaccines candidates
Khalid Shrwani*1,2, Waleed Mahallawi3, Eyad Gadour4,5, Jaber Ghazwani6, Omar Mashi6, Zaki Eisa7, Ahmed Albarrag8,9, Abdullah Algwizani8, Nigel Cunliffe1, Qibo Zhang10, 1University of Liverpool, UK, 2Department of Virology, Public Health Authority, Jazan, Saudi Arabia, 3Taibah University, Saudi Arabia, 4University Hospitals of Morecambe Bay NHS Foundation Trust, UK, 5Zamzam University College, Sudan, 6Public Health Authority, Jazan, Saudi Arabia, 7Saudi Center for Disease Prevention and Control (SCDC), Saudi Arabia, 8Public Health Authority, Saudi Arabia, 9King Saud university, Saudi Arabia, 10University of Surrey., UK

[P1.073] Novel algorithm driven vaccine design framework for optimal population and pathogen variation coverage build for strong cellular and humoral response and memory
Julia Villarroel*, Federico De Masi, Juliet Frederiksen, Claus Lundegaard, ZS Associates, Copenhagen, Denmark

[P1.074] Cholera vaccine clinical trials: a cross-sectional analysis of clinical trials registries
Lindi Mathebula*, Thobile Malinga, Mammekwa Mokgoro, Duduzile Ndwandwe, Charles Wiysonge, Glenda Gray, South African Medical Research Council, South Africa

[P1.075] Return on investment of a 20-valent pneumococcal conjugate vaccine to directly protect adults against pneumococcal disease in England
Diana Mendes1, Mark Atwood2, Reiko Sato3, Andrew Vyse1, James Campling1, Dhwani Hariharan2, Derek Weycker2, Tendai Mugwagwa*4, Jeffrey Vietri3, 1Pfizer UK, UK, 2Policy Analysis Inc, USA, 3Pfizer Inc Pennsylvania, USA, 4Pfizer Inc, USA
[P1.077] Prevalence and impact of persistent symptoms following SARS-CoV-2 infections in UK healthcare workers in the SIREN cohort study
Sarah Foulkes¹, Josie Evans², Jennifer Bishop², Claire Neill¹, Jameel Khawam¹, Colin Brown¹, Susan Hopkins¹, Victoria Hall¹, Lesley price²,³, ¹UK Health Security Agency, UK, ²Public Health Scotland, UK, ³Glasgow Caledonian University, UK

[P1.078] Factors associated with COVID-19 vaccine breakthrough infection in vaccinated UK healthcare workers, a cross-sectional analysis from the VIBRANT, PITCH, and SIREN cohorts
Sarah Foulkes¹, Oliver Galgut², Ana Atti¹, Jameel Khawam¹, jem chalk³, Lizzie Stafford³, Sofia Sampaio³, Jasmin Islam¹, Jean Timeyin¹, Callum Halstead³, Antonia Ho⁴, Kate Templeton⁵, Christopher Duncan⁶, Thushantha de Silva⁷, Lance Turtle⁸, Susan Hopkins¹, Paul Kleneman⁹, Susie Dunachie⁹, Victoria Hall¹, Alex Richter², ¹UK Health Security Agency, UK, ²University of Birmingham, UK, ³University of Oxford, UK, ⁴NHS Greater Glasgow and Clyde, UK, ⁵NHS Lothian, UK, ⁶Newcastle University, UK, ⁷The University of Sheffield, UK, ⁸University of Liverpool, UK, ⁹Oxford University Hospitals NHS Foundation Trust, UK

[P1.079] Development of Toll-Like Receptor-directed adjuvants and incorporation in innovative vaccine formulations against challenging antimicrobial resistant bacterial infections
Ana Rita Franco*, Alessio Romerio, Alice Italia, Valentina Artusa, Federico Lami, Mohamed Monsoor Shaik, Francesco Peri, University of Milan, Italy

[P1.080] F1-based LNP-mRNA vaccine affords protection against bubonic and pneumonic plague
Yinon Levy*, Uri Elia¹, Edo Kon², Hila Cohen¹, Inbal Hazan-Ha'levy², Moshe Aftalion¹, Assaf Ezra², Erez Bar-Haim¹, Gonna Naidu², Yael Diesendruck², Shahar Rotem¹, Nitay Ad-El², Meir Goldsmith², Emanuelle Mamroud¹, Dan Peer², Ofer Cohen¹, ¹Israel Institute for Biological Research, Israel, ²Tel Aviv University, Israel
[P1.081] Local authorities' schemes to improve the influenza vaccination rate for care home staff
Faisal Alsaif*, Michael Twigg1, David Wright2, Amrish Patel1, 
1University of East Anglia, UK, 2University of Leicester, UK

[P1.082] Humoral and cellular responses to mRNA-1273 vaccination in lung transplant recipients with prior infection
Siqi Liu*, Laura van Dijk2, Yvette den Hartog2, Rogier Hoek2, 
Erik Verschuuren1, Corine Geurtsvankessel2, Rory De Vries2, 
Debbie Van Baarle1,4, Coretta Van Leer Buter1, 1University of 
Groningen, The Netherlands, 2Erasmus University Medical 
Center, The Netherlands, 3University Medical Center 
Rotterdam, The Netherlands, 4Center for Infectious Disease 
Control, National Institute for Public Health and the 
Environment, Bilthoven, The Netherlands

[P1.083] Hybrid immunity in SARS-CoV-2: the paediatric story
Youjia Zhong*, Elizabeth Huiwen Tham2, Lynette Pei-Chi Shek2, 
Eng Eong Ooi1, 1Duke-NUS Medical School Program in Emerging Infectious Diseases, Singapore, 2National University of Singapore Yong Loo Lin School of Medicine, Singapore

[P1.084] Receipt of the influenza vaccine is the greatest factor associated with pneumococcal vaccine uptake amongst the elderly
Mncengeli Sibanda*, JC Meyer, Rosemary Burnett, Sefako Makgatho Health Sciences University, South Africa

[P1.086] Immunogenicity of a chimeric SARS-CoV-2 virus-like particle in mice
Bac Tran Le, Jung-Eun Park*, Chungnam National University, Republic of Korea
[P1.087] Obesity is a risk factor for symptomatic flaviviral infection
Ayesa Syenina*1,2, Christine Tham1,2, Danny Tng1,3,4, Valerie Chew1,2, Jia Xin Yee1,2, Yanshan Leong1,2, Eugenia Ong1,2, Jenny Low1,2,3, Eng Eong Ooi1,2,3,5, 1Duke-NUS Medical School, Singapore, 2Singhealth Duke-NUS Academic Medical Centre, Singapore, 3Singapore General Hospital, Singapore, 4Duke-NUS Medical Academic Clinical Programme, Singapore, 5National University of Singapore, Singapore

[P1.088] Identifying priority groups for CMV vaccination in China: A modeling study
Gang Qin1, Meng-Zhao Yin1, Yuan-Yuan Gu2, Jun-Tao Shu*3, Bin Zhang1, Min Su1, Lu-Ping Zhang1, Yin-Hua Jiang1, 1Affiliated Hospital of Nantong University, China, 2Macquarie University, Australia, 3Nantong University, China

[P1.089] Pre-clinical evaluation of vaccine efficacy against Tuberculosis
Rebecca Winsbury*, Simon Clark, Service UK Health Security Agency - Porton, UK

[P1.090] Humoral immune response against XBB.1.5 and BQ.1.1 SARS-CoV-2 variants of a fourth dose of PHH-1V vaccine in adult subject: Preliminary results of HIPRA-HH-2 extension study
Salome de Cambra Florensa*, Sandra Moros, Antonio Barreiro, Antonio Prenafeta, Laia Madrenas, Manuel Cañete, Julia Corominas, Irina Güell, Tersa Prat, Laura Ferrer, HIPRA HUMAN HEALTH, Spain

[P1.091] A study on the improvement of in vivo potency assay of botulinum toxin products for national lot release system
Kyung Sik Yoon*, Hanbit Bong, Jiyun Seo, Won Gyo Jang, Jeong Nam Woo, InYeong Hwang, Jongwon Kim, National Institute of Food and Drug Safety Evaluation, Republic of Korea
[P1.092] Lessons learned from COVID vaccine hesitancy in teenagers during COVID19 pandemic in USA
Meher Garg1, Ruchi Gupta*2,3,1, Springfield School, USA, Springfield Clinic LLP, USA, Southern Illinois University, USA

[P1.093] Purification of virus-like particles by liquid chromatography as candidate vaccines.
Pedro Martín-Reyes*1, Nicola J Stonehouse2, David J Rowlands2, University of Leeds, UK, University of Leeds, UK

[P1.094] Pneumococcal serotypes associated with invasive pneumococcal disease and carriage in UK children - potential impact of a 20-valent pneumococcal conjugate vaccine
Carole Czudek*, Andrew Vyse, Gillian Ellsbury, Pfizer Ltd, Walton Oaks, UK

[P1.095] Field monitoring of the implementation of polio supplementary immunization activities following circulating Vaccine-Derived Polio Virus Type 2 (cVDPV2) Outbreak in Aceh, Indonesia
Sherli Karolina*, Lulu Ariyantheny Dewi, Ratih Oktri Nanda, Prima Yosephine, Gertrudis Tandy, Ministry of Health of the Republic of Indonesia, Indonesia

[P1.096] Effects of freezing media on cell viability for dendritic cell-based immunotherapy
Alberto José da Silva Duarte*, Bruna Tiaki Tiyo, Telma Miyuki Oshiro, Laís Teodoro da Silva, Universidade de Sao Paulo, Brazil

[P1.097] Genomics advancements in vaccine design and development in low and middle income economies
Samson Muuo Nzou*1, Robinson Irweka1, Matthew Munyao1, Esther Kinyuru2, Tonny Nyandwaro1, Peter Rotich1, Caroline Njoroge1, Joanne Yego1, Eberhard Zeyhle3, Ann Mwangi1, Kenya Medical Research Institute, Kenya, Ministry of Health, Nakuru County, Kenya, Meru University of Science and Technology, Kenya
[P1.098] Development of a Nipah virus model of disease
Stephen Findlay-Wilson, Stuart Dowall, Lucy Flett*, Javier Salguero, Roger Hewson, UKHSA, UK

[P1.099] Utility of language model and physics-based approaches in modifying MHC Class-I immune-visibility for the design of vaccines and therapeutics
Hans-Christof Gasser*, Diego Oyarzun, Ajitha Rajan, Javier Alfaro, The University of Edinburgh, UK

[P1.100] Seasonality of Guillain-Barré Syndrome during vaccination against SARS-CoV-2: A country-wide analysis of vaccines in Mexico
Yaneth Tapia-Morales¹, Miguel García-Grimshaw¹, Sergio Iván Valdés-Ferrer*¹, ²Salvador Zubiran National Institute of Medical Sciences and Nutrition, Mexico, ²Northwell Health Feinstein Institutes for Medical Research, USA

[P1.101] Toxicity of aluminum adjuvant in rabies vaccine: a case study
Subhash Chand*, Jaipal Meena, Harit Kasana, Faraz Sheikh, Gurminder Bindra, Shikha Yadav, Harish Chander, National Institute of Biologicals, India

[P1.102] SARS-CoV2 spike protein expression as an Identification in quality control testing for adenovector based Covid-19 vaccine
Ade Ajay Kumar¹, Jaipal Meena¹, Harit Kasana¹, Anup Anvikar¹, Harish Chander*, ¹National Institute of Biologicals, India, ²National Institute of Biologicals, India

[P1.103] Quality testing for vaccines: Need of the hour
Harit Kasana, Jaipal Meena, Harish Chander*, Archana Syal, Subhash Chand, National Institute of Biologicals, India

[P2.001] The abundance of selected lipopolysaccharide-rich bacteria and Toll-like Receptor 4 expression are significantly associated with rotavirus vaccine shedding
Lerato Kgosana*, Mapaseka Seheri, Cliff Magwira, Sefako Makgatho Health Sciences University, South Africa
[P2.002] A versatile and powerful dendritic cell-targeting platform to induce sustained protective immunity upon single dose immunization
Sylvie Alonso¹, Mireille Lahoud², Nicholas Cheang¹, ¹National University of Singapore, Singapore, ²Monash University, Australia

[P2.003] Predictors of uptake of childhood immunisation by mothers in an urban community in Osun state
Olapeju Esimai*¹, Titilayo Adeyanju², ¹Obafemi Awolowo University, Nigeria, ²Obafemi Awolowo University Teaching Hospital, Nigeria

[P2.004] Adjuvanted influenza vaccination in the elderly and its impact on public healthcare system resources within the Republic of Ireland - An influenza and SARS-CoV-2 co-circulation approach
Van Hung Nguyen¹, Mansoor Ashraf², Joaquin Mould-Quevedo³, Timothy Schrire*¹, ¹Seqirus USA Inc, USA, ²Seqirus, UK, ³Seqirus USA Inc, USA

[P2.005] Association between body mass index (BMI) and safety and immunogenicity to COVID-19 vaccination in different sex
Yujing Fan*¹, Ricky, Ruiqi Zhang¹, Ka-Yi Leung¹, Danlei Liu¹, Ka-Wa Khong², Hoi-Yan Lam², Xiaochun Xie², Kwok-Hung Chan², Ivan, Fan-Ngai Hung², ¹The University of Hong Kong, Hong Kong, ²The University of Hong Kong, Hong Kong

[P2.006] Novel ways to drive catch-up vaccination of adult migrants in UK primary care: a pilot study
Alison F Crawshaw¹, Lucy P Goldsmith¹, Anna Deal¹,², Jessica Carter¹, Felicity Knights¹, Farah Seedat¹, Michiy Iwami¹, Fatima Wurie³, Azeem Majeed⁴, Sally Hargreaves*¹, ¹St George's University of London, UK, ²London School of Hygiene & Tropical Medicine, UK, ³Office for Health Improvement and Disparities, UK, ⁴Imperial College London, UK
[P2.007] **Adherence to tetanus prophylaxis guidelines among trauma patients in Japan**
Sachiko Ono*1, Mikio Nakajima2, Hayato Yamana3, Nobuaki Michihata4, Kohei Uemura1, Yosuke Ono5, Hideo Yasunaga1, 1The University of Tokyo, Japan, 2Tokyo Metropolitan Hiroo Hospital, Japan, 3Jichi Medical University, Japan, 4Chiba Cancer Center Research Institute, Japan, 5National Defense Medical College, Japan

[P2.008] **Residual toxicity testing of vaccine matrices against neonatal bovine diarrhoea and ovine abortion with the Limulus Amoebocyte Lysate (LAL) test: Preliminary data**
Antonella Di Paolo*, Lucia Anzalone, Claudia Colabella, Rosario Liberti, Andrea Felici, Monica Cagiola, Istituto Zooprofilattico Sperimentale dell'Umbria e delle Marche "Togo Rosati", Italy

[P2.009] **Duration of influenza vaccine effectiveness in the elderly in Japan: A retrospective cohort study using large-scale population-based registry data**
Kohei Uemura*1, Sachiko Ono1, Nobuaki Michihata2, Hayato Yamana3, Hideo Yasunaga1, 1The University of Tokyo, Japan, 2Chiba Cancer Center Research Institute, Japan, 3Jichi Medical University, Japan

[P2.010] **Assessment of the programmatic suitability and user acceptability of delivery devices for the prevention of respiratory syncytial virus in infants**
Manjari Quintanar-Solares*1, Denise Habimana2, Collrane Frivold1, Courtney Jarrahiay1, 1PATH, USA, 2PATH, Switzerland

[P2.011] **Cellular and humoral immunity against different SARS-CoV-2 variants is detectable but reduced in vaccinated kidney transplant patients**
Laura Thümmler*1, Anja Gäckler1, Maren Bormann1, Sandra Ciesek2,3,4, Marek Widera2, Hana Rohn1, Neslinur Fisenkci1, Mona Otte1, Mira Alt1, Ulf Dittmer1, Peter Horn1, Oliver Witzke1, Adalbert Krawczyk1, Monika Lindemann1, 1University of Duisburg-Essen, Germany, 2University Hospital Frankfurt, Germany, 3Goethe-University, Germany, 4Fraunhofer Institute for Molecular Biology and Applied Ecology (IME), Germany
[P2.012] Development and characterization of a live attenuated influenza A/H1N1pdm09 virus vaccine master donor virus candidate
Svetlana Shcherbik*1, Nicholas Pearce2, Maarja Toots2,3, Tatiana Bousse2, David Wentworth2, John Steel2, 1Centers for Disease Control and Prevention, USA, 2Centers for Disease Control and Prevention, USA, 3Battelle Memorial Institute, USA

[P2.013] VaxCheck: The development and testing of a clinical decision-making adult vaccine tool for community pharmacists
Nancy Waite1, Sherilyn Houle*1, Molly Yang2, Elizabeth Vernon-Wilson2, Madeleine Rivard1, Alice Lau2, 1University of Waterloo, Canada, 2WholeHealth Partners, Canada

[P2.014] Increasing vaccination service capacity by use of injection-certified pharmacy technicians in community pharmacies: A qualitative analysis of best practices
Nancy Waite, Mathew DeMarco, Sherilyn Houle*, University of Waterloo, Canada

[P2.015] Mapping of the cold-adapted and temperature sensitive phenotypes of a live attenuated influenza A/H1N1pdm09 virus vaccine candidate
Brenda M. Calderon*, Svetlana Shcherbik, Nicholas Pearce, David Wentworth, John Steel, Centers for Disease Control and Prevention, USA

[P2.016] Promoter mutations in the novel “OP7” influenza defective interfering particle intended for use as antiviral
Julita Piasecka*1, Daniel Rüdiger1, Sascha Kupke1, Udo Reich1,2, 1Max Planck Institute for Dynamics of Complex Technical Systems, Germany, 2Otto von Guericke University, Germany
[P2.017] Establishment of an improved ATP assay method for BCG vaccine potency testing
Pyong-Gon Moon*¹, Donglin Yi², So Jeong Lee¹, TaeHyung Kim¹, Inyoung Lee¹, Joon-Ik Ahn¹, InYeong Hwang¹, Jongwon Kim¹, ¹National Institute of Food and Drug Safety Evaluation, Republic of Korea,²National Institute of Food and Drug Safety Evaluation, Republic of Korea

[P2.018] Improving vaccination coverage through community pharmacy services; the COVID-19 experience and implications for policy review in Nigeria
Yejide Oseni¹,², Ukamaka Okafor¹, Taofik Odukoya*³, Hamidu Oloyedun⁴, Abiodun Ajibade⁵, Yusuff Azeez², Abigail Okonu¹, Oladapo Adetunji⁶, ¹Pharmacy Council of Nigeria, Nigeria,²Obafemi Awolowo University, Nigeria,³Vanguard Pharmacy Ltd, Nigeria,⁴Oyo State Ministry of Health, Nigeria,⁵Alvid Nigeria Ltd, Nigeria,⁶University of Ibadan, Nigeria

[P2.019] Estimating the burden of adult accident and emergency respiratory attendances in England that are due to respiratory syncytial virus
Andrew Vyse*¹, Elizabeth Begier², Hamish Graham¹, Hannah Wright¹, ¹Pfizer International Ltd (UK), UK,²Pfizer Inc, USA

[P2.020] Codon pair deoptimization (CPD)-attenuated PRRSV-1 vaccination exhibit immunity to virulent PRRSV challenge in pigs
Hyang-Sim Lee*, Animal and Plant Quarantine Agency, Republic of Korea

[P2.021] Comparison of immune response in Omicron SARS-CoV-2 breakthrough infection across BNT162b2 and CoronaVac vaccinated adults
Xiaochun Xie*, Ruiqi Zhang, Danlei Liu, Yujing Fan, Kwok Hung Chan, Ivan Fan-Ngai Hung, The University of Hong Kong, Hong Kong
[P2.022] A One-Year Follow-Up Evaluation of Frontline Healthcare Workers' Knowledge After Adverse Events Following Immunization (AEFI) Surveillance Training in Six Districts in Malawi
Lapani Ngala¹, Sandra Kiplagat², Christine Kihembo³, Joseph Magoola³, Rhoda Chado⁴, Kondwani Mmanga*¹, Anderson Ndalama⁵, Esther Chirwa⁶, Boston Zimba⁶, Donnie Mategula⁷, Mike Chisema⁴, Jane Gidudu², ¹African Field Epidemiology Network, Malawi,²Centre for Disease Control and Prevention, USA,³African Field Epidemiology Network, Uganda,⁴Expanded Programme on Immunization, Ministry of Health, Malawi,⁵Pharmacy Medicines Regulatory Authority, Malawi,⁶World Health Organization, Malawi,⁷Kamuzu University of Health Sciences, Malawi

[P2.023] Estimating costs associated with pediatric Respiratory Syncytial Virus infection managed in the hospital setting in England
Rebecca Butfield*, Jack Said, Pfizer Ltd, UK

[P2.024] Estimating costs associated with adult Respiratory Syncytial Virus infection managed in the hospital setting in England
Rebecca Butfield*, Jack Said, Pfizer Ltd, UK

[P2.025] Immunological correlates of Type III Interferon (IFN-λ3) pre-treatment of chicken cells against Avian Influenza Virus (AlV) infection
Sucharita Bhowmick*, Amirul Islam Mallick, Indian Institute of Science Education and Research Kolkata, India
[P2.026] Mapping zero-dose children and missed communities identified through school vaccination screening in Zambia

[P2.027] Immunogenicity of a subunit Nipah virus vaccine adjuvanted with polyphosphazene and administered via the intranasal route
Dominique Promeneur, Glorie Lazaro, Becky Nowak, Alexander Marin, Nairuti Patel, Stefan Hamm, Alexander Andrianov, Victor Leyva Grado*, 1AuroVaccines LLC, USA, 2Institute for Bioscience and Biotechnology Research, USA

[P2.028] Determinants of COVID-19 vaccine early acceptance and non-acceptance among health care workers based at a tertiary care institution, New Delhi, India
Sumit Malhotra*, Kalaivani Mani, All India Institute of Medical Sciences, New Delhi, India

[P2.029] Co-administration of OVX836, NP-based universal influenza vaccine candidate, with conventional ha-based influenza vaccine: results of phase 2a clinical trial
Paul Willems, Jessika Tourneur, Delphine Guyon-Gellin, Alexandre Le Vert*, Florence Nicolas, Osivax, France
[P2.030] Evaluation of two infectious Bovine Rhinotracheitis (IBR) marker vaccines against Bubaline Alphaherpesvirus 1 (BuHV-1) in water buffalo (Bubalus bubalis) after challenge infection with wild-type BuHV-1
Giovanna Cappelli¹, Stefano Petrini*², Carlo Grassi³, Giovanna De Matteis³, Francesco Grandoni³, Giorgio Galiero¹, Giovanna Fusco¹, Esterina De Carlo¹, Alessandra Martucciello¹, ¹Istituto Zooprofilattico Sperimentale del Mezzogiorno, Italy, ²Istituto Zooprofilattico Sperimentale Umbria-Marche, “Togo Rosati,”, Italy, ³CREA-Council for Agricultural Research and Economics-Research Centre for Animal Production and Aquaculture, Italy

[P2.031] Assessing the feasibility of school-based vaccination screening and catch-up vaccination in 2 districts in Zambia
Alvira Z Hasan*¹, Aliness M Dombola², Christine Prosperi¹, Webster Mufwambi², Rodgers Sakala², Kelvin Kapungu², Gershom Chongwe², Prachi Singh¹, Qiulin Wang¹, Megan P Powell¹, Kennedy Siputuma³, Malalu Mulundika³, Stella Chewe³, Chisanga Mpundu³, Francis Mwansa⁴, Constance Sakala⁴, Elicah Kamiji⁴, Shaun A Truelove³, William J Moss¹, Simon Mutembo¹, ¹Johns Hopkins University, USA, ²Tropical Diseases Research Centre, Zambia, ³Ministry of Education, Government of Republic of Zambia, Zambia, ⁴Ministry of Health, Government of Republic of Zambia, Zambia

[P2.032] Cross-reactivity of the immune response triggered in a phase 2 study by a novel, broad-spectrum influenza vaccine candidate
Philippe Moris, Charlotte Primard, Alexandre Le Vert*, Florence Nicolas, Osivax, France

[P2.033] Challenges and communication strategies in COVID-19 vaccination: Insights from vaccinators in Tuscany, Italy
Vieri Lastrucci*¹, Giorgia Alderotti², Martina Corvo¹, Primo Buscemi³, Guglielmo Bonaccorsi³, Chiara Lorini³, Maria José Caldes², ¹Meyer Children’s hospital IRCCS, Italy, ²Meyer Children’s Hospital IRCCS, Italy, ³University of Florence, Italy
[P2.034] **Rotavirus vaccine product switch: Experience of 4 states of India**
Amanjot Kaur¹, Arindam Ray², Amrita Kumari*¹, Syed F. Qaudri¹, Rashmi Mehra¹, Seema Singh Koshal¹, Rhythm Hora¹, Pradeep Haldar¹, Arup Deb Roy¹, ¹John Snow Inc India, India, ²Bill & Melinda Gates Foundation India, India

[P2.035] **Comparative analysis for antibody persistence after OPV, sIPV and cIPV received in Japan**
Fuka Kikuchi*¹,², Ai Hayashi¹,³, Satoru Arai¹, Michiya Hasegawa⁴, Yasutaka Yamashita⁵, Masae Itamochi⁶, Miyabi Ito⁷, Emi Hirose⁵, Atsuko Sakurai⁸, Yoko Ikeda⁹, Yuji Hanada¹⁰, Mami Nagashima⁴, Yuka Ootsuka⁵, Noriko Aoki⁵, Hideki Tani⁶, Katsuhiko Sato⁷, Rika Komagome⁸, Yoko Aoki⁹, Hidetaka Yoshizumi¹⁰, Minetaro Arita¹, Hajime Kamiya¹, Motoi Suzuki¹, ¹National Institute of Infectious Diseases, Japan, ²Tokyo University of Agriculture and Technology, Japan, ³Tohoku University School of Medicine, Japan, ⁴Tokyo Metropolitan Institute of Public Health, Japan, ⁵Ehime Prefectural Institute of Public Health and Environmental Science, Japan, ⁶Toyama Institute of Health, Japan, ⁷Aichi Prefectural Institute of Public Health, Japan, ⁸Hokkaido Institute of Public Health, Japan, ⁹Yamagata Prefectural Institute of Public Health, Japan, ¹⁰Chiba Prefectural Institute of Public Health, Japan

[P2.036] **Enablers and barriers to rotavirus vaccine coverage in Assam, India- A qualitative study**
Rashmi Mehra¹, Arindam Ray², Sabita Das³, Biman Kusum Chowdhury³, Seema Singh Koshal¹, Rhythm Hora¹, Amrita Kumari*¹, Amanjot Kaur¹, Syed F Quadri¹, Arup Deb Roy¹, ¹John Snow Inc India, India, ²Bill & Melinda Gates Foundation India, India, ³Government of Assam, India

[P2.037] **Influenza vaccine hesitancy among healthcare workers in a tertiary care hospital in India: preliminary results of an ongoing study**
Rakesh Kumar*, Ritvik Amarchand, Prerna Malik, Vijaydeep Siddharth, Anand Krishnan, All India Institute of Medical Sciences, New Delhi, India
**[P2.038]** Dynamics of lymphocyte subsets during the COVID-19 vaccination process in Japanese general population
Takuma Furukawa*1, Goki Yamada2, Akiko Matsumoto1, Chiharu Iwasaka1,3, Takeshi Sawada1, Mikiko Tokiya1, Mikako Horita1, Megumi Hara1, Saga University, Japan, Kagoshima University, Japan, National Institutes of Biomedical Innovation, Health and Nutrition, Japan

**[P2.039]** Study of the ability of passive immunity to induce clinical protection against Bovine alphaherpesvirus-1 (BoHV-1) after challenge infection with wild-type (wt) BoHV-1
Cecilia Righi*1, Alessandra Martucciello2, Paola Gobbi1, Giovanna Cappelli2, Giulia Costantino1, Silvia Pirani1, Michela Pela1, Carlo Grassi2, Monica Giammarioli1, Giulio Viola3, Esterina De Carlo2, Francesco Feliziani1, Stefano Petrini1, National Reference Centre for Infectious Bovine Rhinotracheitis (IBR), Istituto Zooprofilattico Sperimentale Umbria-Marche, “Togo Rosati,” Perugia, Italy, Italy, National Reference Centre for Hygiene and Technology of Breeding and Buffalo Production, Istituto Zooprofilattico Sperimentale del Mezzogiorno, Salerno, Italy, Italy, Veterinary Practioner, Macerata, Italy, Italy

**[P2.040]** Comprehensive pictorial holistic packaging of information aided with indigenous tools for behavior change interventions helped in reducing vaccine hesitancy among parents or caretakers in Uttar Pradesh, India
Rina Dey*, Dr. Roma Solomon, Abhishek Gupta, CORE Group Partners Project, India

**[P2.041]** Lot quality assurance sampling for field monitoring of a new vaccine: a pilot study
Rhythm Hora*1, Arindam Ray2, Rashmi Mehra1, Seema Singh Koshal1, Amrita Kumari1, Syed F Quadri1, Amanjot Kaur1, Pradeep Haldar1, Arup Deb Roy1, John Snow Inc India, India, Bill & Melinda Gates Foundation India, India
[P2.042] Factors associated with not uptake of COVID-19 vaccine and vaccine hesitancy among people with severe mental illness in Bangladesh
Asiful Chowdhury*1, Alex Mitchell2, Helal Uddin Ahmed3, Amina Khan4, A. T. Nizami5, Gerardo A. Zavala2, Najma Siddiqi2,6,7, Kamran Siddiqi2,6, Rumana Huque1, 1ARK Foundation, Dhaka, Bangladesh, Bangladesh, 2Department of Health Sciences, University of York, York UK, UK, 3National Institute of Mental Health & Hospital, Dhaka, Bangladesh, Bangladesh, 4The Initiative, Pakistan, Pakistan, 5Institute of Psychiatry (IoP), Rawalpindi, Pakistan, Pakistan, 6Hull York Medical School, UK, UK, 7Bradford District Care NHS Foundation Trust, UK, UK

[P2.043] Post-vaccine HAI antibody kinetics are driven by pre-existing immune status
David Hodgson*1, Annette Fox2, Sheena Sullivan2, Adam Kucharski1, 1London School of Hygiene & Tropical Medicine, UK, 2The University of Melbourne, Australia

[P2.044] The development and evaluation of theory-based social media intervention using a human-centred design approach to address vaccine hesitancy: a case study of Chinese students in the UK
Lan Li*, Patty Kostkova, University College London, UK

[P2.045] Rapid field assessment to understand the low reporting of newly introduced vaccine in the UIP of Gujarat, India
Seema Singh Koshal1, Arindam Ray2, Divya Rathee1, Rashmi Mehra1, Amanjot Kaur1, Rhythm Hora*1, Amrita Kumari1, Syed F. Quadri1, Pradeep Haldar1, Arup Deb Roy1, 1John Snow Inc India, India, 2Bill & Melinda Gates Foundation India, India

[P2.046] Post-vaccination clinical safety and immunogenicity of maternal purified Respiratory Syncytial Virus (RSV) of protein vaccine administration in pregnant women: meta-analysis of randomised trials
Muhammad Pradhika Mapindra*1, Muhammad Pradhiki Mahindra2, Howard Clark2, Jens Madsen2, 1University College London Institute for Women's Health, UK, 2University College London Institute for Women's Health, UK
[P2.047] SARS-CoV-2 vaccine hesitancy in China: A national cross-sectional survey in community setting
Tianshuo Zhao*1, Xikun Li2, Zhuangye Wang3, Li Wang4, Wenguo Jiang5, Yu Ha6, Hui Li7, Linyi Chen1, Xianming Cai1, Yaqiong Liu1, Qingbin Lu1, Fuqiang Cui1, 1Peking University School of Public Health, China, 2Harbin First Specialized Hospital, China, 3Dezhou Center for Disease Control and Prevention, China, 4Suzhou Center for Disease Control and Prevention, China, 5Jining Center for Disease Control and Prevention, China, 6Jiuzhangou Center for Disease Control and Prevention, China, 7Gansu Provincial Center for Disease Prevention and Control, China

[P2.048] The Vaccine Training Barometer: An online survey tool for assessing Healthcare providers' training needs and confidence in answering vaccine-related questions
Greet Hendrickx*, Sara Valckx, Aurélie De Waele, Pierre Van Damme, University of Antwerp, Belgium

[P2.049] Influenza vaccination uptake in the Netherlands: a qualitative study among health care workers and elderly in Amsterdam
Jantine van Wijlick*1,2, Christopher Pell1,3,4, 1Amsterdam Institute for Global Health and Development, The Netherlands, 2Amsterdam Institute for Social Science Research (University of Amsterdam), The Netherlands, 3Global Health (Amsterdam UMC Location AMC, The Netherlands, 4Centre for Social Science and Global Health (University of Amsterdam), The Netherlands

[P2.050] Impact of statins on Influenza-Like Illness by influenza vaccination status in adults aged 65y and older: a cohort study using the UK Clinical Practice Research Datalink
Adam Streeter*1,2,3, William Henley2, Ian Wellaway4, Lauren Rodgers2, Andrea Shelly2, Sarah Walker4, Fergus Hamilton5, William Hamilton2, 1University of Münster, Germany, 2University of Exeter Medical School, UK, 3University of Plymouth, UK, 4University of Exeter, UK, 5University of Bristol, UK
[P2.051] Real-world effects of statins at the time of influenza vaccination on the risk of acute respiratory infections and pneumonia in older adults: a cohort study using the UK Clinical Practice Research Datalink
William Henley*1, Adam Streeter2,3,1, Andrea Shelly1, Ian Wellaway4, Lauren Rodgers1, Sarah Walker1, Fergus Hamilton5, William Hamilton1, 1University of Exeter Medical School, UK, 2University of Münster, Germany, 3University of Plymouth, UK, 4University of Exeter, UK, 5University of Bristol, UK

[P2.052] Immunogenicity, safety and tolerability of intradermal COVID-19 vaccination strategy in immunocompromised patients: a prospective, randomized trial
Ruiqi Zhang*, Ka-Wa Khong, Ka-Yi Leung, Danlei Liu, Yujing Fan, Hoi-Yan Lam, Linlei Chen, Xiaochun Xie, Brian Pui-Chun Chan, Kelvin Kai-Wang To, Kwok-Yung Yuen, Kwok-Hung Chan, Ivan Fan-Ngai Hung, University of Hong Kong, Hong Kong

[P2.053] Building up facilitators, breaking down barriers: a narrative review mapping behavioral factors that impact vaccine trial participation
Toni Claessens*, Aurélie De Waele, Greet Hendrickx, University of Antwerp, Belgium

[P2.054] Associations between vaccine attitudes and COVID-19 precautionary behaviors: A social network study from the northeastern United States
Aditya Khanna*1, Mollie Monnig2, Tori Davis2, Peter Monti1, 1Brown University School of Public Health, USA, 2Brown University School of Public Health, USA

[P2.055] Exploring vaccine hesitancy towards COVID-19 vaccine among Métis Nation of Ontario citizens using latent class analysis
Ashok Chaurasia1, Kim Eliane2, Keith King*3, Shelley Gonneville4, Sarah Edwards2, Ornell Douglas1, Jeff Kwong2,5, Graham Mecredy2, Jennifer Walker2,6, Martin Cooke1, 1University of Waterloo, Canada, 2Institute for Clinical Evaluative Sciences, Canada, 3University of Alberta, Canada, 4Métis Nation of Ontario, Canada, 5University of Toronto, Canada, 6McMaster University, Canada
[P2.056] The vaccination equity education coalition: experiential education on vaccine confidence to advance health and digital equity for all
Hajar Shirley*1,2, Kaitlyn Camperlino2, 1Rutgers University, USA, 2inclusive Health Innovation Together, USA

[P2.057] Perspectives on vaccination among Métis Nation of Ontario citizens who remain unvaccinated
Tasha Shields*1, Ornella Douglas1, Keith King2, Shelley Gonneville3, Sarah Edwards4, Ashok Chaurasia1, Jeff Kwong4,5, Graham Mecredy4, Jennifer Walker4,6, Martin Cooke1, 1University of Waterloo, Canada, 2University of Alberta, Canada, 3Métis Nation of Ontario, Canada, 4Institute for Clinical Evaluative Sciences, Canada, 5University of Toronto, Canada, 6McMaster University, Canada

[P2.058] Confidence, complacency and collective responsibility were important factors for COVID-19 vaccination among Métis Nation of Ontario Citizens
Keith King*1, Hira Khan2, Shelley Gonneville3, Sarah Edwards2, Ashok Chaurasia4, Ornella Douglas4, Jeff Kwong2,5, Graham Mecredy2, Jennifer Walker2,6, Martin Cooke4, 1University of Alberta, Canada, 2Institute for Clinical Evaluative Sciences, Canada, 3Métis Nation of Ontario, Canada, 4University of Waterloo, Canada, 5University of Toronto, Canada, 6McMaster University, Canada

[P2.059] In shots we trust: Vaccination as a tool for American diplomacy then and now
Sara Jane Samuel*, Columbia University, USA

[P2.060] Assessing community and individual drivers of vaccination- Adapting and applying the BeSD framework to identify enablers and barriers to COVID-19 vaccination in India
Gopal Krishna Soni2, Surbhi Seth*1, Sonal Kakkar1, Jessica Shearear2, Sanjay Kapur1, Grace Chee3, 1John Snow India, India, 2PATH, USA, 3John Snow Inc Washington DC, USA
[P2.061] Swine Fc-conjugated serotype O foot-and-mouth disease virus-like particles play an important role in host inflammatory responses via PPAR α
Hye-Mi Lee*, Jae-Yeon Park, Hyun-Jin Shin, Chungnam National University, Republic of Korea

[P2.062] Adenovirus mediated expression of porcine epidemic diarrhea virus (PEDV) s1-ferritin nanoparticles induced significant neutralizing antibody response against PEDV in mouse models
M. S. B. W. T. M. Nipuna Sudaraka Tennakoon*, Hyun-Jin Shin, Chungnam National University, Republic of Korea

[P2.063] New vaccine development for foot and mouth disease by virus like particles conjugated with swine fc molecule
Jae-Yeon Park*, Hyun-Jin Shin, Chungnam National University, Republic of Korea

[P2.064] Design and development of a multi-epitope vaccine prototype against SARS-CoV-2
Iliyan Manoylov1, Nikolina Mihaylova1, Nikola Ralchev1, Silviya Bragyanova1, Mariyana Atanasova2, Ivan Dimitrov2, Irini Doytchinova2, Vladimir Petkov3, Sonya Tsibranska3, Slavka Tcholakova3, Andrey Tchorbanov*1, 1Bulgarian Academy of Sciences, Bulgaria, 2Medical University-Sofia, Bulgaria, 3Sofia University, Bulgaria

[P2.065] Addressing vaccine hesitancy: planning for annual COVID-19 vaccination among inner city residents in Vancouver, Canada
Brian Conway*1,2, Shawn Sharma1, Girogia Toniato1, Shana Yi1, Rossitta Yung1, 1Vancouver Infectious Diseases Centre, Canada, 2Simon Fraser University, Canada

[P2.066] Long-term vaccine durability of COVID-19 vaccines
Kirsty Morrison*1, Lucy Cullen1, Emmanuel Ezeoke2, Vera Chua2, Allan James2, Christopher Sullivan2, Ross McQueenie2, Kimberly Marsh2, 1Public Health Scotland, UK, 2Public Health Scotland Glasgow Office, UK
Laura Macdonald*1, Cheryl Gibbons1, Michelle Falconer1, William Malcolm2,1, Esme Wright1, Mike Birnie1, Kat Karacaoglu1, Marianne Alsina2, Claire Cameron1, 1Public Health Scotland Glasgow Office, UK, 2NHS National Services Scotland, UK

[P2.068] Proposal to adopt a new joint external evaluation tool to build vaccine confidence
Lawrence Stanberry*1, Tariro Makadzange2, Wilmot James3, Janan Dietrich4, Susan Rosenthal1, Natalia Pasternak Taschner5, Shabir Madhi4, 1Columbia University Irving Medical Center, USA, 2Mutala Research, Zimbabwe, 3Brown University, USA, 4University of the Witwatersrand Johannesburg, South Africa, 5Instituto Questão de Ciência, Brazil

[P2.069] Global and regional burden of attributable and associated bacterial antimicrobial resistance avertable by vaccination: modelling study
Chaelin Kim1, Marianne Holm2, Isabel Frost3, Mateusz Hasso-Agopsowicz3, Kaja Abbas*1, 1London School of Hygiene & Tropical Medicine, UK, 2International Vaccine Institute, Republic of Korea, 3World Health Organisation, Switzerland

[P2.070] Safety evaluation in pregnant ewes of the Rift Valley Fever live-attenuated vaccine candidate 40Fp8
Pedro J. Sanchez-Cordon*1, Celia Alonso1, Oscar García García2, Rafael Gonzalez Cano3, Belen Borrego1, Alejandro Brun1, 1Animal Health Research Center, Spain, 2National Association of Breeders of Manchegan Sheep (AGRAMA), Spain, 3Regional Institute of Castilla-La Mancha for Agri-Food and Forest Research and Development (IRIAF), Spain

[P2.071] Reliable intradermal vaccination with VAX-ID using prediction models for controlled depth allowing use of fractional dose as part of pandemic preparedness programs
Koen Beyers*, Daniele Scalco Vasconcelos, Momen Rbeihat, Vanessa Vankerckhoven, Idevax BV, Belgium
Nuala Healy¹, Debbie Maguire², Graham McGowan³, Claire Cameron*¹, Lorna Willocks⁴, ¹Public Health Scotland, UK, ²Scottish Government Population Health Directorate, UK, ³Public Health Scotland, UK, ⁴Scottish Government, UK

[P2.074] Understanding the working modalities of Neglected Tropical Diseases (NTDs): a leverage mechanism for implementing COVID-19 vaccine awareness and uptake in Yobe and Ebonyi states
Sidney Sampson, Sunday Atobatele, Akolade Jimoh*, Saheed Isiaka, Sydani Group, Nigeria

[P2.075] Peptide-encapsulated PLGA nanoparticles as a novel vaccine strategy against *Leishmania infantum*
Clara Hurtado-Morillas*, Alicia Mas, José A Orden, Javier Carrión, Abel Martínez-Rodrigo, Gustavo Domínguez-Bernal, Complutense University of Madrid, Spain

[P2.076] Intranasal delivery of *Salmonella* OMVs decorated with *Chlamydia trachomatis* antigens induces specific local and systemic immune responses in mice
Dung T. Huynh*¹,², Emanuele Nolfi³, Alice J. A. M. Sijts³, Joen Luijink¹,², ¹Abera Bioscience AB, Uppsala, Sweden, ²Vrije Universiteit Amsterdam, The Netherlands, ³Utrecht University, The Netherlands
Real-world-evidence on different COVID-19 vaccines combinations’ effectiveness in six electronic healthcare data sources from four pan-European countries

Fabio Riefolo*1,2, Belén Castillo Cano3, Mar Maria Martin3, Davide Messina4, Roel Elbers5, Dorieke Brink-Kwakkel5, Felipe Villalobos6, Ylenia Ingrasciotta7, Patricia Garcia-Poza3, Karin Swart-Polinder8, Patrick Souverein9, Luis Carlos Saiz10, Carlo Alberto Bissacco6, Leire Leache11, Michele Tari12, Salvatore Crisafulli7, Elisa Barbieri13, Luca Stona14, Xavier Garcia de Albeniz15, Satu Siiskonen16, Lamiae Grimaldi17, Tiago Vaz5, Rosa Gini4,2, Olaf Klungel9, Elisa Martin Merino3,2, 1Teamit Institute, Partnerships, Barcelona Health Hub, Barcelona, Spain, 2Vaccine monitoring Collaboration for Europe, Brussels, Belgium, 3Spanish Agency of Medicines and Medical Devices-AEMPS, Madrid, Spain, 4Agenzia Regionale di Sanita’ Toscana, Florence, Italy, 5University Medical Center Utrecht, The Netherlands, 6Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain, 7University of Verona, Italy, 8PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands, 9Utrecht University, The Netherlands, 10Navarre Health Service, Pamplona, Spain, 11Navarre Health Service, Spain, 12Caserta Local Health Unit, Caserta, Italy, 13University of Padua, Italy, 14Fondazione Penta ONLUS, Padova, Italy, 15RTI-Health Solutions, Barcelona, Spain, 16Utrecht Institute for Pharmaceutical Sciences, The Netherlands, 17l’Assistance Publique-Hôpitaux de Paris (APHP), University Paris-Saclay, Paris, France

Immunogenicity and protective efficacy of recombinant porcine epidemic diarrhoea virus spike protein

Hsing Chieh Wu, Doan Thi Thu Dung, Min Kung Hsu, Hsian Yu Wang, Chun Yen Chu*, National Pingtung University of Science and Technology, Taiwan
[P2.079] A systematic review of barriers and enablers associated with uptake of influenza vaccine among care home staff
Faisal Alsaif*, Michael Twigg1, Sion Scott2, Annie Blyth1, David Wright2, Amrish Patel1, 1University of East Anglia, UK, 2University of Leicester, UK

[P2.080] EBHS recombinant vaccine prototype: development and standardization of a simple and cost-effective production procedure
Claudia Colabella*, Lucia Anzalone, Elisabetta Manuali, Rosario Liberti, Antonella Di Paolo, Giulio Severi, Monica Cagiola, Antonio De Giuseppe, Istituto Zooprofilattico Sperimentale dell’Umbria e delle Marche “Togo Rosati”, Italy

[P2.081] Factors associated with trust and acceptance of mRNA technology: A review of current evidence
Ana Bolio*, Prima Alam, Heidi Larson, London School of Hygiene & Tropical Medicine, UK

[P2.082] Oral cholera vaccine coverage following a targeted mass-campaign in Goma, Democratic Republic of the Congo
Emily Briskin*, Stéphane Hans Bateyi Mustafa2, Rachel Mahamba3, Laurent Akilimali4, Deka Kabunga5, Janvier Kubuya5, Klaudia Porten1, Placide Okitayemba Welo4, Anaïs Broban1, 1Epicentre, France, 2National Vaccination Program, Democratic Republic of Congo, 3MSF/Epicentre, Democratic Republic of Congo, 4National Plan for Cholera Elimination (PNECHOL), Democratic Republic of Congo, 5Provincial Health Division, Democratic Republic of Congo
Factors affecting oral cholera vaccination status after a mass preventative campaign in rural Bukama health zone, Democratic Republic of the Congo, 2022

Waning of specific antibodies against Delta and Omicron variants five month after a third dose of BNT162b2 SARS-CoV-2 vaccine in elderly individuals
Yun Shan Goh*, Angeline Rouers, Siew-Wai Fong, Nicole Zhuo, Pei Xiang Hor, Chiew Yee Loh, Yuling Huang, Vanessa Neo, Isaac Kam, Bei Wang, Eve Ngoh, Siti Nazihah Mohd Salleh, Raphael Lee, Surinder Pada, Louisa Sun, Desmond Ong, Jyoti Somani, Eng Sing Lee, Sebastian Maurer-Stroh, Cheng-I Wang, Ee Chee Ren, Yee Sin Leo, David Lye, Barnaby Young, Lisa Ng, Laurent Renia, A*STAR ID Labs, Singapore, Singapore Immunology Network, Singapore, Bioinformatics Institute, Singapore, Ng Teng Fong General Hospital, Singapore, Alexandra Hospital, Singapore, National University Polyclinic, Singapore, National University of Singapore, Singapore, National Healthcare Group Polyclinics, Singapore, National Centre for Infectious Diseases, Singapore
[P2.085] Heterologous prime-boost Zika virus vaccination supplies a comprehensive humoral and cellular immunity in mouse model
Giuditta De Lorenzo*¹,², Rapeepat Tandavanitj¹,³, Lorena Preciado-Llanes⁴, Ricardo Sanchez-Velazquez¹, Raissa Prado Rocha⁴, Young Chan Kim⁴, Arturo Reyes-Sandoval⁴,⁵, Arvind Patel¹, ¹MRC-University of Glasgow Centre for Virus Research, UK, ²AREA Science Park, Italy, ³Research and Development Institute, Thailand, ⁴University of Oxford, UK, ⁵Instituto Politécnico Nacional, Mexico

[P2.086] Effectiveness of HPV vaccination in preventing high grade cervical disease and cancer diagnoses in Wales
Lauren O'Gorman*¹, Malorie Perry¹, Simon Cottrell¹, Katie Walbeoff², Dyfed Huws³, Helen Clayton⁴, Louise Richards⁵, ¹Public Health Wales Vaccine Preventable Disease Programme, UK, ²Public Health Wales Cervical Screening Wales, UK, ³Public Health Wales Welsh Cancer Intelligence and Surveillance Unit, UK, ⁴Public Health Wales Informatics Division, UK, ⁵Digital Health and Care Wales, UK

[P2.087] Validation of a double-color ELISpot assay of IFN-γ and IL-4 production in human Peripheral Blood Mononuclear Cells
Giulia Fantoni*, VisMederi srl, Italy, University of Siena, Italy

[P2.088] Establishment and validation of a high-throughput micro-neutralization assay for Respiratory Syncytial Virus (subtypes A and B)
Leonardo Armini*, VisMederi srl, Italy, University of Siena, Italy

Chenoa Cassidy-Matthews*¹,², David Zamar², Sherri Pooyak³, Margo Pearce⁴, Jeffrey Reading⁵, Martin Schechter¹, Patricia Spittal¹,², ¹The University of British Columbia, Canada, ²BC Children's Hospital Research Institute, Canada, ³University of Victoria, Canada, ⁴Fraser Health, Canada, ⁵Simon Fraser University, Canada
[P2.091] Effectiveness of second BNT162b2 mRNA booster doses in protecting against SARS-CoV-2 infection during the Omicron sub-variant waves; the UK SIREN study June 2022 to March 2023
Sarah Foulkes¹, Peter Kirwan², Victoria Hall*¹, Ferdinando Insalata¹, anne presanis², Andre Charlett¹, daniela de Angelis², Susan Hopkins¹, ¹UK Health Security Agency, UK, ²University of Cambridge, UK

[P2.092] Progress towards a virus-free polio vaccine: a virus-like particle (VLP) vaccine as a safe alternative to current vaccines
David Rowlands, Nicola Stonehouse, Pedro Martín-Reyes*, University of Leeds, UK

[P2.093] The CATCH-UP study; determinants of HPV vaccine uptake in a Dutch campaign for young adults
Chaja Kater*, Adriette Oostvogels, Dirk Hoevenaars, Milly Haverkort, GGD Kennemerland, The Netherlands

[P2.094] Levels of confidence, complacency, constraints and collective responsibility predict COVID-19 vaccination behaviour amongst South African school educators
Kesentseng Mahlaba*, Dineo Mmakgwale, Maria Kau, Rosemary Burnett, Johanna Meyer, Sefako Makgatho Health Sciences University, South Africa

[P2.095] Seasonal influenza virus vaccine effectiveness through recombinant neuraminidase on VLPs
Leticia Guzman Ruiz*, Irene Hoxie², Miriam Klausberger¹, Florian Krammer², Alois Jungbauer¹,³, Reingard Grabherr¹, ¹University of Natural Resources and Life Sciences Vienna, Austria, ²The Mount Sinai Hospital, USA, ³Austrian Centre of Industrial Biotechnology, Vienna, Austria

[P2.096] Bivalent SARS-CoV-2 mRNA vaccination provides optimal protection against XBB.1 infection in a murine challenge model
Jordan Clark*, Michael Scherm, Nisreen Okba, Brian Monahan, Juan Manuel Carreño, Anass Abbad, Viviana Simon, Florian Krammer, Icahn School of Medicine at Mount Sinai, USA
[P2.097] The epidemiological profile of typhoid fever in Greater Glasgow and Clyde between April 2014 and March 2023: evidence of the intercontinental spread of extensively-drug resistant typhoid fever from Pakistan to Scotland
Jacob Asplin*, NHS Greater Glasgow and Clyde, Public Health Protection Unit, UK

[P2.098] Sociodemographic and economic factors associated with the willingness to accept a free COVID-19 vaccine among households in Nigeria
Oghenowede Eyawo*1, Shenyi Pan2, Mishel Mahboob3, Telma Oroh4, Uchechukwu Ugoji5, 1School of Global Health, York University, Canada, 2Department of Statistics, University of British Columbia, Canada, 3York University School of Kinesiology and Health Science, Canada, 4Coventry University, UK, 5Salem Clinic & Maternity, Warri, Nigeria

[P2.099] Measles susceptibility in Scotland: preventing a resurgence
Cheryl Gibbons*, Melissa Llano, Neil Perkins, Salomi Barkat, Laura MacDonald, Michelle Falconer, Claire Cameron, Public Health Scotland, UK

[P2.100] Differential antibody dynamics to multiple MPOX antigens following two doses of MVA-BN (IMVANEX) in a longitudinal cohort
Bethany Hicks*, Scott Jones2, Cathy Rowe2, Ashley Otter3, 1UK Health Security Agency, UK, 2UK Health Security Agency, UK, 3UK Health Security Agency, UK

[P2.101] Opt-out vaccination of COVID-19 in selected municipalities in Japan
Hiroshi Nishura*, Kyoto University, Japan

[P2.102] Emphasizing the importance of Shariah Islamic perspectives in vaccine manufacturing
Hazlin Kadir Shahar*, Department of Islamic Development Malaysia, Malaysia